RedHill Biopharma Advances Opaganib For Ebola Treatment With BARDA Funding, Aiming To Tackle Global Health Preparedness

redhill biopharma正在利用BARDA资金推进Opaganib用于埃博拉治疗，旨在解决全球卫生应对准备工作。

Benzinga · 2024/10/14 19:13

The U.S. government's Biomedical Advanced Research and Development Authority (BARDA) selected opaganib for joint development & funding as a medical countermeasure (MCM) to treat Ebola virus disease (EBOV)
The funding advances opaganib's positive development progress to date on the expected FDA Animal Rule pathway toward potential approval as an MCM for EBOV
Recent U.S. Army-funded studies showed that opaganib delivered a statistically significant increase in survival in an in vivo EBOV model. The BARDA research and development contract provides initial funding for the collaboration, in pursuit of advancing opaganib to mitigate infection and contain EBOV outbreaks
This year marks the 10th anniversary of the West Africa Ebola epidemic in which 11,000 people died, and there is still an urgent need for effective and useable therapies, with EBOV proving fatal in around half of all cases according to the World Health Organization (WHO)1
Opaganib, a novel potentially broad-acting drug, has shown mutation-resistant antiviral and anti-inflammatory activity, likely to directly impact vascular health - one of the main targets for EBOV dysfunction. It is believed to be the first host-directed molecule to show activity in EBOV in vivo and represents an alternative host-directed therapeutic strategy for biodefense and global health preparedness. Additional U.S. government collaborations with opaganib are ongoing
Significant geopolitical and logistical challenges exist in managing outbreaks of disease and there is an urgent need for safe and effective, oral, small molecule therapeutics that can be stored and easily distributed and administered in an outbreak

美国政府的生物医药高级研究与发展局（BARDA）选择了opaganib进行联合开发和资助，作为治疗埃博拉病毒疾病的医疗对策（MCM）
该资助将推动opaganib迄今在预期的FDA动物规则途径上的积极研发进展，以望获批准作为EBOV的MCM
最近美国陆军资助的研究显示，opaganib在体EBOV模型中显著提高生存率。BARDA的研究与发展合同为该合作提供初期资助，以推动opaganib的发展，减轻感染并控制EBOV爆发
今年是西非埃博拉疫情爆发十周年，导致11,000人死亡，仍然迫切需要有效且可用的疗法。据世界卫生组织（WHO）称，EBOV导致近一半病例死亡
Opaganib是一种新型潜在广谱药物，显示出耐变抗病毒和抗炎活性，可能直接影响血管健康，这是EBOV失调的主要靶标之一。它被认为是首个在EBOV体内展现活性的宿主定向分子，并代表了一种用于生物防御和全球卫生准备的替代宿主定向治疗策略。美国政府与opaganib的合作正在继续
在管理疾病爆发时存在重大的地缘政治和后勤挑战，急需安全有效的口服小分子治疗剂，可以储存、易于分发和在爆发中使用

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。更多信息

RedHill Biopharma Advances Opaganib For Ebola Treatment With BARDA Funding, Aiming To Tackle Global Health Preparedness

RedHill Biopharma Advances Opaganib For Ebola Treatment With BARDA Funding, Aiming To Tackle Global Health Preparedness

热门市场机会

热门讨论

热门讨论

RedHill Biopharma Advances Opaganib For Ebola Treatment With BARDA Funding, Aiming To Tackle Global Health Preparedness

RedHill Biopharma Advances Opaganib For Ebola Treatment With BARDA Funding, Aiming To Tackle Global Health Preparedness

风险及免责提示

热门市场机会

热门讨论

热门讨论

声明